ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

HVO Hvivo Plc

29.25
0.00 (0.00%)
Last Updated: 08:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hvivo Plc LSE:HVO London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 29.25 29.00 29.50 29.25 29.25 29.25 3,203 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 56.04M 16.12M 0.0237 12.34 199.01M

hVIVO plc Confirmation of Change of Name to hVIVO plc (3601K)

16/04/2015 7:01am

UK Regulatory


Hvivo (LSE:HVO)
Historical Stock Chart


From Aug 2019 to Aug 2024

Click Here for more Hvivo Charts.

TIDMHVO

RNS Number : 3601K

hVIVO plc

16 April 2015

For immediate release 07:00: 16 April 2015

HVIVO PLC

("hVIVO" or the "Company")

CONFIRMATION OF CHANGE OF NAME TO HVIVO PLC

Further to its announcement on 13 April 2015, the Company confirms that its name has now changed from Retroscreen Virology Group plc to hVIVO plc (AIM: HVO).

Trading in the Company's shares on AIM under its new name will take effect at 8.00am this morning.

For further information please contact:

hVIVO plc +44 207 756 1300

Kym Denny (CEO)

Graham Yeatman (FD)

Media Enquiries +44 203 021 3933 / +44 7854 979 420

Colin Paterson (Director of Marketing, Communication and Public Relations)

Numis Securities Limited +44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Michael Burke (Corporate Broking)

Notes to Editors:

hVIVO plc ("hVIVO") is a life sciences company pioneering a technology platform of human disease models to accelerate drug development and discovery in respiratory and infectious diseases. Based in the UK, hVIVO has conducted over 40 clinical studies, involving more than 1950 volunteers for a range of leading industry, governmental and academic clients.

This information is provided by RNS

The company news service from the London Stock Exchange

END

CANPKPDKFBKDKQD

1 Year Hvivo Chart

1 Year Hvivo Chart

1 Month Hvivo Chart

1 Month Hvivo Chart

Your Recent History

Delayed Upgrade Clock